Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
26.8M
-
Number of holders
-
50
-
Total 13F shares, excl. options
-
6.9M
-
Shares change
-
+913K
-
Total reported value, excl. options
-
$28.8M
-
Value change
-
+$3.93M
-
Put/Call ratio
-
0.04
-
Number of buys
-
31
-
Number of sells
-
-10
-
Price
-
$4.17
Significant Holders of Eton Pharmaceuticals, Inc. - Common Stock (ETON) as of Q3 2023
58 filings reported holding ETON - Eton Pharmaceuticals, Inc. - Common Stock as of Q3 2023.
Eton Pharmaceuticals, Inc. - Common Stock (ETON) has 50 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.9M shares
of 26.8M outstanding shares and own 25.7% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (2.43M shares), VANGUARD GROUP INC (976K shares), Westside Investment Management, Inc. (528K shares), PARADIGM CAPITAL MANAGEMENT INC/NY (300K shares), BlackRock Inc. (285K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (271K shares), EAM Investors, LLC (257K shares), Acuitas Investments, LLC (219K shares), GEODE CAPITAL MANAGEMENT, LLC (218K shares), and AMERIPRISE FINANCIAL INC (187K shares).
This table shows the top 50 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.